Your Daily Biotechnology Briefing

BioNTech and DualityBio Report Strong Phase 2 Efficacy for Endometrial Cancer Drug

• BioNTech SE and DualityBio announced positive primary analysis results on April 11, 2026, for trastuzumab pamirtecan (BNT323/DB-1303), an antibody-drug conjugate, in patients with HER2-expressing, recurrent endometrial cancer. The study demonstrated a confirmed objective response rate of 49.3% in patients who had received prior checkpoint inhibitor treatment, and 47.9% across all evaluated patients, with a median progression-free survival of 8.1 months. Notably, the drug showed clinically meaningful efficacy across all HER2 immunohistochemistry expression levels, including lower expression settings typically underserved by existing targeted therapies.

  GurufocusEuropean Biotechnology

• In a significant global oncology expansion, China's National Medical Products Administration (NMPA) approved Amgen's tarlatamab (Imdelltra) for previously treated extensive-stage small cell lung cancer (ES-SCLC) on April 12, 2026. This approval, with regional development and commercialization led by BeOne Medicines, materially strengthens the drug's global commercial reach beyond its 2024 FDA approval, reinforcing the growing global scalability of bispecific T-cell engagers.

  Oncodaily

• AbbVie showcased late-breaking Phase 2 data for mirvetuximab soravtansine-gynx (ELAHERE®) in platinum-sensitive ovarian cancer (PSOC) at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on April 12, 2026. Results from the IMGN853-0420 trial indicated an objective response rate of 62.7% for ELAHERE® plus carboplatin, followed by continuation of mirvetuximab soravtansine monotherapy, in patients with ≥50% folate receptor alpha (FRα)-expressing PSOC.

  Prnewswire